Rossari Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Rossari Biotech yıllık ortalama 16% oranında kazançlarını artırırken, Chemicals sektöründe kazançlar growing at 14.6% annual. Gelirler growing yılda ortalama 13.4% oranında artmaktadır. Rossari Biotech'in özkaynak karlılığı 12.4% ve net marjı 7.2%'dir.

Anahtar bilgiler

16.0%

Kazanç büyüme oranı

13.5%

EPS büyüme oranı

Chemicals Sektör Büyümesi	17.7%
Gelir büyüme oranı	13.4%
Özkaynak getirisi	12.4%
Net Marj	7.2%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Rossari Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BSE:543213 Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	19,245	1,388	1,189
30 Jun 24	19,096	1,364	1,072
31 Mar 24	18,306	1,307	1,098
31 Dec 23	17,643	1,255	1,084
30 Sep 23	16,898	1,168	1,065
30 Jun 23	16,318	1,078	1,031
31 Mar 23	16,559	1,073	1,039
31 Dec 22	16,883	1,027	997
30 Sep 22	17,275	995	957
30 Jun 22	16,866	1,018	855
31 Mar 22	14,830	977	735
31 Dec 21	12,623	957	610
30 Sep 21	10,438	948	516
30 Jun 21	8,310	892	462
31 Mar 21	7,093	802	456
31 Dec 20	6,507	729	423
30 Sep 20	6,031	695	415
30 Jun 20	5,818	666	389
31 Mar 20	6,001	653	396
31 Mar 19	5,162	457	301
31 Mar 18	2,922	254	213
31 Mar 17	2,350	143	195

Kaliteli Kazançlar: 543213 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 543213 'nin mevcut net kar marjları (7.2%) geçen yılın (6.9%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 543213 şirketinin kazancı son 5 yılda yılda 16% oranında arttı.

Büyüme Hızlandırma: 543213 'un son bir yıldaki kazanç büyümesi ( 18.8% ) 5 yıllık ortalamasını (yıllık 16% ) aşıyor.

Kazançlar vs. Sektör: 543213 geçen yılki kazanç büyümesi ( 18.8% ) Chemicals sektörünün 8% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 543213 'nin Özsermaye Getirisi ( 12.4% ) düşük olarak değerlendiriliyor.

Rossari Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Recent updates

Now 22% undervalued after recent price drop

Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent Director

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024

Price target increased by 7.6% to ₹951

Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024

Upcoming dividend of ₹0.50 per share

Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Consensus revenue estimates increase by 26%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors

New 90-day high: ₹1,036

Third quarter 2021 earnings released: EPS ₹4.16

Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹859

New 90-day high: ₹839

First half earnings released

Rossari Biotech Limited to Report Q2, 2021 Results on Oct 24, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi